Menu
GWAS Study

Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Blacks.

Olson NC, Raffield LM, Moxley AH et al.

34706549 PubMed ID
GWAS Study Type
3492 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

ON
Olson NC
RL
Raffield LM
MA
Moxley AH
MT
Miller-Fleming TW
AP
Auer PL
FN
Franceschini N
ND
Ngo D
TT
Thornton TA
LE
Lange EM
LY
Li Y
ND
Nickerson DA
ZN
Zakai NA
GR
Gerszten RE
CN
Cox NJ
CA
Correa A
MK
Mohlke KL
RA
Reiner AP
Chapter II

Abstract

Summary of the research findings

suPAR (Soluble urokinase plasminogen activator receptor) has emerged as an important biomarker of coagulation, inflammation, and cardiovascular disease (CVD) risk. The contribution of suPAR to CVD risk and its genetic influence in Black populations have not been evaluated.

3,492 African American individuals

Chapter III

Study Statistics

Key metrics and study information

3492
Total Participants
GWAS
Study Type
No
Replicated
African unspecified
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.